April 13, 2017 - 16:21 — Elizabeth Wright
Legislation to create “transparency” in drug costs has been introduced in dozens of state legislatures across the country, purportedly to understand how prescription drugs are priced. While details vary from state to state, all the bills would require pharmaceutical manufacturers to provide reams of pricing and cost data, much of it proprietary, to state officials. Often the bills will drag in other private-sector entities involved in pharmaceutical pricing negotiations, such as pharmacy benefit managers (PBMs) and insurers.
